Pharmacology of GP IIb-IIIa platelet inhibitors, part IV

Journal of Interventional Cardiology

Volumn 13, Issue 4, 2000, Pages 243-254

  David Talley, J ^a,b  

^a Cardiology Associates of Paducah   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ARTICLE; BLEEDING; DRUG BINDING; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOGENICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

EID: 0033816786     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2000.tb00299.x     Document Type: Article

References (69)

1. Pathogenesis of acute ischemic coronary syndromes
2. GP IIb-IIIa: The responsive integrin
3. New antiplatelet agents: Platelet GP IIb/IIIa antagonists
4. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
5. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 thal
6. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 Pilot (SPEED) dose-ranging trial
7. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial
8. Basilar artery rethrombosis: Successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor
9. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb-IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications
10. Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis
11. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy
12. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor
13. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
14. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
15. Preclinical development of c7E3 Fab; A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
16. 3
17. Role of platelets in restenosis after percutaneous coronary revascularization
18. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
19. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
20. Clinical pharmacology of eptifibatide
21. Disintegrins: A family of integrin inhibitory proteins from viper venoms
22. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms
23. Barbourin: A GP IIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri
24. Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb-IIIa
25. Integrilin (TM): Synthetic peptides against the platelet glycoprotein IIb/IIIa receptor
26. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor
27. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GP IIb/IIIa receptors
28. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischaemic heart disease
29. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
30. Pharmacokinetics and pharmacodynamics of MK-383, a selective nonpeptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
31. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI study group
32. Bleeding time: A guide to its diagnostic and clinical utility
33. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine
34. Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition
35. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
36. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
37. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation
38. 2+ on GP IIb-IIIa interactions with Integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
39. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: Implications for assay methodology and comparison of different antagonists
40. The Xylum Clot Signature Analyzer: A dynamic flow system that simulates vascular injury
41. Quantifying GP IIb/IIIa receptor binding using 2 monoclonal antibodies: Discriminating abciximab and small molecular weight antagonists
42. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation
43. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs
44. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy
45. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors
46. Anti-GP IIb/IIIa antibodies: Powerful tools to investigate function and regulation of an integrin
47. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
48. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization
49. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
50. Pharmacodynamics of the GP IIb-IIIa antagonist Integrelin: Phase I clinical studies in normal healthy volunteers
51. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
52. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II
53. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose integrilin(TM) in coronary intervention: Results of the PRIDE study
54. Design and methodology of the PURSUIT thai: Evaluating eptifibatide for acute ischemic coronary syndromes
55. A heparin-controlled study of MK-383 in unstable angina
56. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
57. Safe use of platelet GP IIb/IIIa inhibitors
58. Stroke in patients with acute coronary syndromes. Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial
59. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation of c7E3 for the Prevention of Ischemic Complications
60. Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention - Caution regarding the combined use of aspirin, ticlopidine and abciximab
61. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
62. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
63. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
64. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
65. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
66. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
67. Thrombocytopenia with GP IIb/IIIa inhibitors: A meta-analysis
68. Abciximab readministration for coronary interventions: Is it safe?
69. 3)